Skip to main content
Premium Trial:

Request an Annual Quote

DoubleTwist Licenses Prophecy Database to GPC Biotech

NEW YORK, Oct. 16 – DoubleTwist has licensed its Prophecy database and tools suite to GPC Biotech, the company said on Tuesday.

Financial terms of the agreement were not disclosed.

"DoubleTwist's Prophecy suite gives us comprehensive access to annotated public genome data and effective tools for their use,” Greg Hamm, vice president for bioinformatics at GPC Biotech said in a statement. “We are looking forward to mining this valuable data set.”

DoubleTwist, of Oakland, Calif., recently announced the release of its third-generation Prophecy database, which the company says includes an assembled genome of more than 35 databases onto a single genomic scaffold.

GPC Biotech, based in Munich, Germany, is a genomics- and proteomics-based drug-discovery company focused on drugs in oncology, infectious diseases, and immunology.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.